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Abstract
Background: The current vaccine against tuberculosis (TB), BCG, has failed to control TB worldwide and the protective
efficacy is moreover limited to 10–15 years. A vaccine that could efficiently boost a BCG-induced immune response and thus
prolong protective immunity would therefore have a significant impact on the global TB-burden.
Methods/Findings: In the present study we show that the fusion protein HyVac4 (H4), consisting of the mycobacterial
antigens Ag85B and TB10.4, given in the adjuvant IC31H or DDA/MPL effectively boosted and prolonged immunity induced
by BCG, leading to improved protection against infection with virulent M. tuberculosis (M.tb). Increased protection
correlated with an increased percentage of TB10.4 specific IFNc/TNFa/IL-2 or TNFa/IL-2 producing CD4 T cells at the site of
infection. Moreover, this vaccine strategy did not compromise the use of ESAT-6 as an accurate correlate of disease
development/vaccine efficacy. Indeed both CD4 and CD8 ESAT-6 specific T cells showed significant correlation with
bacterial levels.
Conclusions/Significance: H4-IC31H can efficiently boost BCG-primed immunity leading to an increased protective anti-
M.tb immune response dominated by IFNc/TNFa/IL-2 or TNFa/IL2 producing CD4 T cells. H4 in the CD4 T cell inducing
adjuvant IC31H is presently in clinical trials.
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Introduction
Tuberculosis (TB) is a chronic respiratory disease caused by
infection with the intracellular pathogen Mycobacterium tuberculosis
(M.tb) which kills almost two million people each year [1].
Infection with M.tb leads to a quiescent latent infection rather
than active disease in more than 90% of infected individuals and
one third of the world’s population is estimated to harbour a latent
TB infection [2,3]. The current vaccine, Bacillus Calmette-Gue ´rin
(BCG), is an attenuated strain of the closely related Mycobacterium
bovis. It protects children against severe disseminated forms of TB.
However, protection against pulmonary disease varies between 0–
80% and is generally lowest in endemic areas [4]. Due to the
protective efficacy against paediatric forms of disseminated TB
and the worldwide coverage through the WHO Extended
Program of Immunization (EPI), BCG is not likely to be replaced
within the near future.
BCG has been shown to induce a T helper cell 1 (Th1) biased
immune response and it has been suggested that gradual
exhaustion of an insufficient pool of central memory T cells
induced by BCG may be responsible for the declining protection
against TB, which is estimated to last for only 10–15 years [5,6,7].
Several controlled trials have been performed to evaluate the effect
of revaccinating with BCG in order to boost BCG immunity and
T cell memory. However, these trials demonstrated that revacci-
nation with BCG did not improve protection [8,9], probably
because BCG induced immunity from the first dose inhibits the
response of the second BCG-dose. In line with this, continuous
exposure to environmental mycobacteria has been suggested as an
important factor leading to the limited protection of BCG
[4,10,11]. Although still debated in the field, animal studies have
shown that exposure to environmental mycobacteria did in fact
inhibit survival of BCG after vaccination, leading to decreased
protection [12]. Importantly, the protection of adjuvanted subunit
vaccines is not affected by environmental mycobacteria exposure.
Thus, environmental mycobacteria could be a major factor
responsible for the limited efficacy of BCG and accordingly
development of an improved vaccine to boost the partial
protective immune response in BCG vaccinated individuals is of
high priority in the effort to control TB.
In the search for new and improved vaccines against TB much
attention has focused on secreted mycobacterial proteins. These
proteins were indeed shown to be protective in animals and also
recognized in infected humans [13,14,15]. Our laboratory has
developed a subunit vaccine named Hybrid1 (H1) consisting of two
fused protein antigens, Ag85B and ESAT-6, both present in short
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; term culture filtrate and recognized in infected individuals. H1 is
protectiveinseveralanimalmodels[16,17]andproducedpromising
results in a clinical phase I trial [18] when formulated in the IC31H
adjuvant. However, as ESAT-6 is an extremely valuable diagnostic
toolincorporatedintoseveralcommercialdiagnostickits[19,20],and
H1 immunization may interfere with TB-diagnosis, we therefore
replaced ESAT-6 with TB10.4 to generate the vaccine H4 (Ag85B-
TB10.4)[21].TB10.4waschosenasthisproteinishighlyexpressedby
BCG and M.tb and strongly recognized in BCG vaccinated and/or
infected humans. H4 on its own has been showed to induce efficient
anti-TB protection in mice when given in IC31H or DDA/MPL
adjuvants [21,22].
InthepresentstudyweevaluatedforthefirsttimeinthemurineTB
modeltheabilityoftheH4-vaccineinIC31H(orDDA/MPL)toboost
and prolong the immune response induced by BCG. We found that
H4 efficiently boosted effector and memory CD4 T cells primed by
BCG, leading to a stronger and prolonged immune response
dominated by multifunctional T cells. This in turn improved the
protectionagainstinfectionwithM.tb.Finallywealsoobservedthat
ESAT-6specificCD4aswellasCD8Tcellscorrelatedinverselywith
protection against M.tb. The implications of our findings for the
development ofnovelanti TB vaccines arediscussed.
Results
Boosting BCG with H4/IC31 Leads to Enhanced and
Prolonged Immune Responses
We first analysed the ability of H4 given in IC31H to boost
BCG-primed immunity in mice. Mice were immunized as shown
in figure 1A. Two weeks after the first boost with H4-IC31, mice
were sacrificed and the amount of IFNc produced after in vitro
stimulation with each of the vaccine antigens was assessed by
ELISA (Fig. 1B). The results showed that the level of IFNc
produced in the BCG/H4-IC31H boost group after Ag85B-
stimulation of PBMCs (410961458 pg/ml) and splenocytes
(477761360 pg/ml) was strongly increased compared to the
remaining groups, which produced less than 350 pg/ml IFNc
(Fig. 1B, upper panel). Regarding the TB10.4 response both BCG
and BCG/H4-IC31H vaccinated mice produced strong IFNc
responses (Fig. 1B, lower panel). We next evaluated the vaccine-
induced memory response in mice six weeks after the second
booster immunization with H4-IC31H. The results demonstrated
that the BCG/H4-IC31H group exhibited an increased response
compared to the other vaccine groups (Fig. 1C). Stimulating
PBMC’s in vitro with Ag85B led to production of
13145368236 pg/ml IFNc in the BCG/H4-IC31H group,
compared to less than 100 pg/ml in the non-vaccinated or
BCG-vaccinated groups. In mice vaccinated only with H4-IC31
we observed 937962319 pg/ml IFNc. In line with this, TB10.4
stimulation showed a strong increase in the production of IFNc in
the BCG/H4-IC31H group (158979621338 pg/ml), compared to
the non-vaccinated (26612 pg/ml), H4-IC31H (204361107 pg/
ml) and BCG (1222261020 pg/ml) vaccinated mice (Fig. 1C).
Thus, two booster vaccinations with H4-IC31H induced a stronger
and prolonged response against both the vaccine antigens.
Boosting BCG with H4-IC31H Induces Polyfunctional CD4
T Cells with a Memory and Effector Phenotype
We next evaluated the T cell phenotype induced by the different
vaccination strategies. Two weeks after the first H4 booster
immunization, splenocytes and PBMCs were stimulated in vitro
with TB10.4 or Ag85B and the phenotype of responding CD4 T
cells was evaluated by multicolor intracellular cytokine staining
(ICS) and flow cytometry. The groups immunized with BCG and
BCG/H4-IC31H exhibited the strongest responses against
TB10.4. Moreover, increased levels of triple-positive CD4 T cells,
expressing IFNc, TNFa and IL-2 simultaneously, were observed
in the BCG/H4-IC31H group compared to the BCG alone group
in the spleen (Fig. 2A and table 1). The H4-IC31H and BCG/H4-
IC31H groups both showed higher Ag85B responses compared to
naı ¨ve and BCG-immunized mice although the Ag85B levels were
generally lower than the TB10.4 responses (Fig. 2A and table 1). A
similar boosting effect was also observed in the blood 2 weeks after
the first booster vaccination, although responding CD4 T cells in
the blood displayed slightly more effector-like phenotypes (Fig. 2A).
In order to assess the phenotype of the T cells in later phases of
the response, mice were bled six weeks after the second H4-IC31H
immunization and PBMCs were stimulated in vitro with TB10.4 or
Ag85B. The data showed that boosting BCG with H4-IC31H
clearly enhanced the response against TB10.4 in the late phase
(Fig. 2B). The responding CD4 T cells in the BCG/H4-IC31H
group could primarily be divided into cells expressing all three
cytokines (42% of responding CD4 T cells), cells expressing TNFa
and IFNc (32% responding CD4 T cells), or cells expressing
TNFa and IL-2 (8.5% responding CD4 T cells; table 1).
Interestingly, the TB10.4-specific CD4 T cells in the BCG group
were dominated by a IFNc
+ terminally differentiated phenotype.
This could explain the low level of memory immune response
observed following BCG immunization (Fig. 2 B and table 1), as T
cell phenotypes have been suggested to express a specific pattern of
cytokines: 1) IFNc
+TNFa
+IL-2
+ cells representing effector mem-
ory T cells, 2) TNFa
+IL-2
+ cells representing central memory cells
and 3) IFNc
+ cells representing terminally differentiated T cells
[25,26]. We will refer to these designations from here on.
The sameoverallpatternwasseenwhenthecellswerestimulated
with Ag85B (Fig. 2B, lower panel). Thus, at week 6 after the second
boostervaccination,theAg85BresponsewasstrongestintheBCG/
H4-IC31Hgroup(Fig.2B)andtherespondingCD4Tcellsconsisted
of 44%polyfunctional IFNc
+TNFa
+IL-2
+ T cells compared to only
27% in the BCG group which in turn contained relatively more
effector-likeIFNc
+TNFa
+TcellscomparedtotheBCG/H4-IC31H
group (table 1).
Thus, our results show that boosting BCG with H4-IC31H could
enhance and prolong both the response as well as the induction
and maintenance of T cells producing multiple cytokines.
Vaccine-induced Immune Responses after Infection with
Virulent M.tb
An important feature of any vaccine against infection with M.tb
is if/how the vaccine-induced immune responses are maintained
in the face of an infection. To examine this we analysed the
immune responses in the lungs of BCG/H4-IC31H immunized
mice after an aerosol-infection with virulent M.tb. Mice were
infected 7 weeks after the last H4-IC31H booster immunization
and immune responses were evaluated by stimulating lung cells in
vitro with the vaccine antigens or ESAT-6 as a marker of the
infection driven response. Antigen specific T cell phenotypes were
evaluated by ICS and flow cytometry six weeks after infection in
order to assess to which degree the vaccine-induced T cells were
recruited to the lungs and whether the infection influenced the
phenotype of these cells.
TheresultsshowedthatafterinfectiongroupsimmunizedwithH4-
IC31H showed the highest response against Ag85B, whereas groups
immunized with BCG, with or without the H4 boost, exhibited the
highestresponseagainstTB10.4(Fig.3A).Thisisinagreementwith
previousobservationsshowingthatAg85Bisthemostimmunogenic
antigen in H4 [21] whereas BCG induce stronger responses to
TB10.4 [23,27]. Although we observed no major differences in the
H4-IC31H Boosts BCG-Immunity
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wasatrendtowardsamorepolyfunctional/centralmemory(andless
effector-like) phenotype in the BCG/H4-IC31H group (Fig. 3A,
table1).Thus,15.6%ofalllungCD4TcellsrespondedtoTB10.4in
theBCG/H4-IC31Hgroupandofthese61.6%wereIFNc/TNFa/
IL-2producingpolyfunctionalcells(comparedto56.6%intheBCG
group), 20.1% were IFNc
+TNFa
+ effector-like cells (compared to
25.5% in the BCG group), and 11.2% were IL-2
+TNFa
+ central
memory-like T cells (compared to 6.4% in the BCG group) (Fig. 3A
and table1). The highest proportion of IFNc
+TNFa
+ and IFNc
+
effector-like TB10.4-specific T cells was observed in the non-
vaccinated group (Fig. 3A and table 1).
In terms of Ag85B, the strongest responses were seen in the
BCG/H4-IC31H (6.4% of CD4 T cells) and H4-IC31H groups
(5.3% of CD4 T cells; figure 3A and table 1). In the BCG/H4-
IC31H group we generally observed a higher proportion of Ag85B
specific cells represented by polyfunctional triple-positive and
TNFa
+IL-2
+ central memory-like phenotypes, and lower levels of
effector phenotypes TNFa
+IFNc
+ and/or IFNc
+ compared to the
remaining groups (Fig 3A and table 1).
The same overall pattern of responses was also observed in the
spleens of mice (data not shown). Interestingly, in contrast to the
response against the vaccine antigens, the response against ESAT-
6 was dominated by IFNc
+TNFa
+ effector T cells, and was highest
in groups that exhibited the lowest responses against TB10.4
(Fig. 3B). This is most probably because these cells were induced
by the infection itself, which has been shown to induce T cells of
that phenotype [28].
Thus, the BCG/H4-IC31H group showed the highest ability to
induce and maintain a strong response against both of the H4-
contained vaccine antigens during an infection. Furthermore, this
response against the vaccine antigens was in particular dominated
by T cells with a polyfunctional/central memory-like phenotype
that were recruited to the site of infection.
Boosting BCG with H4-IC31H Improves the Protective
Efficacy
We next examined the level of protection against an M.tb-
challenge offered by boosting BCG with H4-IC31H compared to
Figure 1. H4-IC31H boost BCG-primed immune responses and memory. Mice that received BCG were immunized at week 0 and the H4-
IC31H and BCG/H4-IC31H groups were subsequently immunized with H4 in IC31H at 19 and 22 weeks after initiating the experiment (A). The amount
of IFNc produced by splenocytes and PBMCs (pooled from five mice per group) in response to Ag85B and TB10.4 stimulation was evaluated by ELISA.
The responses were evaluated two weeks after the first H4-IC31H immunization (B), and memory responses were evaluated six weeks after the second
immunization in PBMCs pooled from n=15 mice per group (C). Bars represent means and standard deviations of triplicate 72 hour culture-
supernatants. Stimulation with media alone as well as ESAT-6 as a negative control antigen resulted in IFNc secretion below 300 pg/ml (data not
shown). This experiment was repeated once with similar results.
doi:10.1371/journal.pone.0039909.g001
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spleenswereenumeratedsixweeksafterinfection.Theresultsshowed
thatboostingBCGwithH4-IC31HsignificantlyreducedCFUinthe
lung and spleen compared to BCG alone (Fig. 4 and table S1).
OptimalprotectionwithH4formulatedinIC31Hhaspreviouslybeen
demonstrated with three immunizations [21], however, even with a
suboptimal vaccination scheme only involving two immunizations,
H4-IC31H protected mice significantly against M.tb-challenge
(Fig. 4). Moreover, in three different experiments, a similar level of
protection was observed when boosting BCG with H4 in IC31H or
DDA/MPLrangingfrom1.2–1.5log10reductioninCFUinthelungs
comparedtonon-vaccinatedmice.Importantly,weonlyobserveda
significantimprovementinprotectioncomparedtoBCGwhenBCG
itself conferred a reduction of one log10 CFU or less (Fig. S1). The
lower level of protection obtained from BCG in Experiment 1 in
figure S1 is most likely related to the prolonged duration between
BCGandinfectioninthisexperiment(seematerialsandmethodsfor
details).
Monitoring Vaccine-efficacy Through Antigen Specific
CD4 or CD8 Responses after Infection
ESAT-6 is a well-known diagnostic marker of ongoing infection
[21,29,30], and one important factor in the development of
Ag85B-TB10.4 was to reserve ESAT-6 as a diagnostic/infection
marker. We therefore examined the usage of ESAT-6 to predict
protection/infection status when using a BCG booster vaccine
strategy that did not contain ESAT-6. Moreover, we also
examined the correlation between CD4 T cell responses against
the vaccine antigens obtained by flow cytometry shown in figure 3
with the bacterial levels six weeks post infection shown in figure 4.
Our results showed that post infection, the response against
ESAT-6 was highest in non-vaccinated mice which also had the
highest levels of CFU (Fig. 3B, 5A and table S1). Thus, in all the
vaccinated groups we observed a decreased ESAT-6 response after
challenge, which however was most pronounced in the BCG/H4-
IC31H group. By comparing the ESAT-6 response (specifically
ESAT-6 specific IFNc+TNFa+ T cells) with the corresponding
CFU levels, a strong correlation (r
2=0.97, p=0.0179) was
observed between the post-challenge ESAT-6 response and the
outcome of disease/CFU levels. This correlation was not observed
to the same degree with ESAT-6 specific IFNc
+TNFa
+IL2
+ T cells
(r
2=0.79, p=0,11, data not shown). In contrast to ESAT-6
specific CD4 T cells, we observed a significant negative correlation
between the IFNc
+TNFa
+IL2
+ responding CD4 T cells against
TB10.4 and the bacterial levels (r
2=0.99, p=0.0029, figure 5B).
However, there was no correlation between the IFNc
+TNFa
+IL2
+
Ag85B specific T cells in the lungs and the bacterial levels
(r
2=0.28, p=0.4645; figure 5B). Finally, the CD8 T cell response
against ESAT-6 was dominated by IFNc
+TNFa
+ effector cells,
and these cells also showed a significant positive correlation with
the bacterial level (r
2=0.99, p=0.0085; figure S2). Moreover, the
CD8 T cell response against TB10.4 and Ag85B (Fig. S2B) also
correlated with the CFU levels (Fig. S2A).
Figure 2. Boosting BCG with H4-IC31H induces polyfunctional memory and effector CD4 T cells. Mice were immunized as depicted in
figure 1A, and parallel with the ELISA analysis, splenocytes and PBMCs (pooled from n=five mice/group) obtained two weeks after the first H4-IC31H
immunization (A) and PBMCs (pooled from n=15 mice/group) obtained six weeks after the second immunization (B) were used for intracellular
cytokine analysis by flow cytometry. Cells were stimulated with TB10.4 (upper panels) and Ag85B (lower panels). Bars represent the proportions of
CD4 T cell subsets producing different cytokines as indicated on the X-axis. Background levels obtained in media-stimulated samples has been
subtracted. This experiment was repeated once with similar results.
doi:10.1371/journal.pone.0039909.g002
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Percentage of CD4 T cells specific for TB10.4
Time Week 2 post boost 1 spleen Week 2 post boost 1 blood
Group Non vacc. H4-IC31 BCG BCG/H4-IC31 Non vacc. H4-IC31 BCG BCG/H4-IC31
Relative
a (%) Relative (%) Relative
(%)
Relative (%) Relative
a
(%)
Relative
(%)
Relative
(%)
Relative (%)
IFNc
+IL-2
+TNFa
+ 0,00 42,84 23,67 49,74 0,00 1,93 48,93 38,72
IFNc
+IL-2
+TNFa
- 0,00 0,00 0,00 0,00 0,00 0,00 0,35 0,00
IFNc
+IL-2
2TNFa
+ 27,82 0,00 34,57 31,82 0,00 0,00 39,96 44,18
IFNc
+IL-2
2TNFa
- 72,18 0,00 35,90 16,00 16,39 90,18 1,96 13,50
IFNc
-IL-2
+TNFa
+ 0,00 57,16 0,00 2,44 0,00 0,00 2,94 1,95
IFNc
-IL-2
+TNFa
- 0,00 0,00 0,00 0,00 73,77 0,00 0,00 0,15
IFNc
-IL-2
2TNFa
+ 0,00 0,00 5,85 0,00 9,84 7,89 5,87 1,50
Total response 100,00 100,00 100,00 100,00 100,00 100,00 100,00 100,00
Percentage of CD4 T cells
specific for Ag85B
Relative
(%)
Relative
(%)
Relative
(%)
Relative
(%)
Relative
(%)
Relative
(%)
Relative
(%)
Relative
(%)
IFNc
+IL-2
+TNFa
+ 0,00 16,35 2,99 21,94 0,00 7,38 10,53 29,21
IFNc
+IL-2
+TNFa
- 0,00 1,38 0,00 0,00 0,00 3,69 0,00 0,00
IFNc
+IL-2
2TNFa
+ 0,00 13,28 0,00 18,96 39,02 13,20 28,49 32,42
IFNc
+IL-2
2TNFa
- 0,00 0,51 29,75 20,42 0,00 0,00 0,00 0,00
IFNc
-IL-2
+TNFa
+ 0,00 7,15 2,99 17,88 0,00 7,38 0,00 22,46
IFNc
-IL-2
+TNFa
- 100,00 0,00 64,27 20,80 60,98 24,25 60,98 15,91
IFNc
-IL-2
2TNFa
+ 0,00 61,32 0,00 0,00 0,00 44,09 0,00 0,00
Total response 100,00 100,00 100,00 100,00 100,00 100,00 100,00 100,00
Percentage of CD4 T cells specific for TB10.4
Time Week 6 post boost 2 blood Week 6 post post infection lungs
Group Non vacc. H4-IC31 BCG BCG/H4-IC31 Non vacc. H4-IC31 BCG BCG/H4-IC31
Relative
(%)
Relative
(%)
Relative
(%)
Relative
(%)
Relative
(%)
Relative
(%)
Relative
(%)
Relative
(%)
IFNc
+IL-2
+TNFa
+ 0,00 30,05 17,97 42,48 18,63 34,90 56,60 61,62
IFNc
+IL-2
+TNFa
- 0,00 0,00 0,00 0,21 0,33 0,39 0,15 0,05
IFNc
+IL-2
2TNFa
+ 0,00 0,00 15,60 31,93 65,43 39,20 25,53 20,06
IFNc
+IL-2
2TNFa
- 100,00 9,86 58,63 2,66 7,56 3,87 0,57 0,73
IFNc
-IL-2
+TNFa
+ 0,00 49,49 0,00 8,50 1,15 7,65 6,44 11,18
IFNc
-IL-2
+TNFa
- 0,00 10,60 7,81 14,23 0,00 0,30 0,04 0,06
IFNc
-IL-2
2TNFa
+ 0,00 0,00 0,00 0,00 6,89 13,68 10,67 6,30
Total response 100,00 100,00 100,00 100,00 100,00 100,00 100,00 100,00
Percentage of CD4 T cells
specific for Ag85B
Relative
(%)
Relative
(%)
Relative
(%)
Relative
(%)
Relative
(%)
Relative
(%)
Relative
(%)
Relative
(%)
IFNc
+IL-2
+TNFa
+ 0,00 26,43 24,62 42,23 22,56 37,26 42,86 44,01
IFNc
+IL-2
+TNFa
- 0,00 0,00 0,00 0,61 0,10 0,29 0,11 0,12
IFNc
+IL-2
2TNFa
+ 0,00 0,00 33,85 18,35 58,96 25,71 19,99 13,69
IFNc
+IL-2
2TNFa
- 0,00 0,00 0,00 2,82 6,61 2,38 4,53 0,84
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against ESAT-6 correlated significantly with bacterial burden and
inversely with vaccine efficacy. In contrast, the TB10.4 CD4
response showed a positive correlation with vaccine efficacy.
Table 1. Cont.
Percentage of CD4 T cells specific for TB10.4
IFNc
-IL-2
+TNFa
+ 0,00 0,00 8,45 18,30 2,94 13,89 9,69 23,62
IFNc
-IL-2
+TNFa
- 0,00 53,95 16,17 17,70 0,00 0,70 8,49 0,31
IFNc
-IL-2
2TNFa
+ 0,00 19,62 16,92 0,00 8,82 19,77 14,33 17,41
Total response 0,00 100,00 100,00 100,00 100,00 100,00 100,00 100,00
aThe relative proportion of the responding CD4 T cells producing combinations of IFNc,T N F a and/or IL-2 as listed when stimulated with either in vitro TB10.4 or Ag85B,
assessed by intracellular cytokine staining and flowcytometry.
doi:10.1371/journal.pone.0039909.t001
Figure 3. Polyfunctional vaccine specific T cells recruited to the
lungs after infection. Mice immunized as described in the
experiment shown in figure 1 were infected by the aerosol route with
virulent M.tb Erdman seven weeks after the last H4-IC31H booster
immunization. Six weeks after infection lung lymphocytes from three
pools consisting of two half lungs per pool were used from each group
for intracellular cytokine analysis by flow cytometry. Cells were
stimulated with the indicated antigens derived from H4 (Ag85B and
TB10.4; A) or ESAT-6 (B) as specified in the graph. Bars represent the
proportions of lung CD4 T cell subsets producing different cytokines in
response to stimulation as indicated on the X-axis. Background levels
obtained in media-stimulated samples has been deducted. *, p,0.05,
**, p,0.01, ***, p,0.001, proportion of cytokine producing CD4 T cells
subsets compared to non-vaccinated controls using one-way ANOVA
and Tukey’s post-test for multiple comparisons. This experiment was
repeated once with similar results.
doi:10.1371/journal.pone.0039909.g003
Figure 4. Boosting BCG with H4-IC31H improves BCG-derived
protection. Six weeks after infection the level of protection was
assessed in the lungs (upper panel) and spleens (lower panel) of
infected mice. Each data-point represents the log10 CFU value of
individual mice (N=29 for non-vaccinated controls and n=9210 for
the vaccination groups). Means and SEM for each group is indicated. *,
p,0.05, **, p,0.01, ***, p,0.001, using one-way ANOVA and Newman-
Keuls post test for multiple comparisons.
doi:10.1371/journal.pone.0039909.g004
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Boosting with H4-IC31H Induces Protective
Polyfunctional Memory T Cells
In this study we demonstrated that boosting BCG with H4-
IC31H or with H4/DDA/MPL both enhanced and prolonged the
BCG-primed immune response (Fig. 1). This in turn led to a
significant improvement in protection provided that the protection
induced by BCG itself did not exceed 1.1 Log10 reduction in Lung
CFU. This indicate that in the mouse model used in this study only
protection of approximately 1.5 Log10 could be achieved.
Although several studies have shown that BCG protection can
be improved by a subunit or viral based booster vaccine (reviewed
in [31]) few have identified the protective T cell phenotypes. The
improved response in the BCG/H4-IC31H consisted of an
increase in 1) the amounts of CD4 T cells expressing all three
cytokines IFNc, IL-2 and TNFa and 2) an increase in IL-2/
TNFa-expressing cells (Fig. 2). These cell types have been
suggested to represent effector memory- and central memory-like
cells and have furthermore been associated with protection against
intracellular pathogens such as M.tb and Leishmania major [25]. Our
data also showed a correlation between the amounts of triple
positive IL-2
+TNFa
+IFNc
+ vaccine-specific CD4 T cells induced
by immunization and the subsequent level of protection against
infection with M.tb (Fig. 2 and 4). In agreement with our results,
Dey et al. also observed induction of IL-2
+TNFa
+IFNc
+ and IL-
2
+TNFa
+ CD4 T cells after boosting BCG with a DNA-vaccine
encoding a-crystallin (Rv2031c) [32], and boosting BCG with the
MVA-vector expressing Ag85A also resulted in increased numbers
of polyfunctional CD4 T cells with similar phenotypes as observed
in the present study [33]. However, regarding the protective role
of IL-2
+TNFa
+IFNc
+ T cells against M.tb infection there have
been conflicting results [25,33,34,35,36]. An increase in Ag85A-
specific polyfunctional CD4 T cells after boosting BCG with
MVA85A did not improve protection [33]. Moreover, a recent
study showed that humans with active TB displayed high numbers
of IFNc
+IL-2
+TNFa
+ triple positive cells specific for M.tb-
antigens, while latently infected individuals did not. Moreover,
the level of triple positive CD4 T cells actually declined when TB-
patients with active disease were treated [37]. This is in contrast to
other studies which, in line with our results, showed a correlation
between triple positive cells and protection [38]. One difference
that might explain the conflicting observations may relate to the
different antigens used in the different studies.
Correlates of Disease Progression
We observed a significant correlation between protection and
the induction of IFNc
+IL-2
+TNFa
+ triple positive polyfunctional
TB10.4 specific CD4 T cells, indicating an important protective
role for these cells. In contrast, the level of Ag85B-specific CD4 T
cells did not correlate with protection measured 6 weeks after
infection. Interestingly, recent studies have shown that Ag85B in
particular is expressed primarily in the early stages of an infection
with M.tb, i.e. within the first 223 weeks [27,39]. Accordingly
Ag85B immune responses would only be expected to correlate
with bacterial numbers in the early stages of infection.
We have previously shown that Hybrid1 (Ag85B-ESAT-6) is
highly immunogenic in humans and protective against TB in
several animal models and that it could improve BCG conferred
protection [40,41]. We recently showed that exchanging ESAT-6
with TB10.4 resulted in an equally efficient protection against TB
in mice [21]. One advantage of exchanging ESAT-6 with TB10.4
is that it reserves the diagnostic marker ESAT-6 for disease
screening. The current study confirmed the ability of ESAT-6 to
predict the infection level in mice as demonstrated previously
(Fig. 5 and [21]). ESAT-6 responses also correlated with bacterial
burden and pathology severity in cattle [29] and non-human
primates [41]. Moreover, humans recently exposed to M.tb
exhibiting a high ESAT-6 response were more likely to develop
active TB compared to ESAT-6 low-responders [30,42,43].
Interestingly, we also observed a positive correlation between
the bacterial burden and the level of CD8 T cell responses against
ESAT-6 and both the vaccine antigens (Fig. S2). This suggests that
Figure 5. Correlates of protection six weeks after infection. A,
the pulmonary responses obtained using ICS and flow cytometry six
weeks after infection shown in figure 3 after stimulation with ESAT-6 (A)
or the H4-vaccine antigens Ag85B- and TB10.4 (B) were correlated to
the corresponding mean log10 CFU value shown in figure 4. Points
represent mean percentage and SEM (vertical) of CD4 T cells producing
IFNc/TNFa (A) or IFNc/TNFa/IL-2 (B) in response to stimulation with
indicated antigens from 3 pools of two lungs plotted on the y-axis and
mean and SEM (horizontal) log10 CFU values of mice lungs (N=29 for
non-vaccinated controls and n=9210 for the vaccination groups) on
the x-axis. Each point represents one group in the order BCG/H4-IC31,
BCG, H4-IC31, and non vaccinated from left. *, p,0.05, **, p,0.01, using
Pearson’s product-moment correlation coefficient (r) and correlation
test.
doi:10.1371/journal.pone.0039909.g005
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In summary, our results extend the studies of Skeiky et al.
who showed that H4-IC31H could boost BCG immunity leading
to a reduction in CFU levels and slightly prolonged survival in
guinea pigs [44]. In extension of these data we showed that the
mechanism by which H4-IC31H boosted BCG-primed protec-
tive immunity in the mouse model was by inducing an
increased and prolonged response consisting of CD4 T cells
with an effector-memory and central-memory phenotype.
Importantly, our vaccine strategy did not compromise ESAT-6
based diagnostics. H4-IC31H is presently in clinical trials as a
BCG-booster vaccine.
Materials and Methods
Ethics Statement
Experiments were conducted in accordance with the regulations
set forward by the Danish Ministry of Justice and animal
protection committees by Danish Animal Experiments Inspector-
ate Permit 2009/561-1655 or 2004-561-868 and in compliance
with European Community Directive 86/609 and the U.S.
Association for Laboratory Animal Care recommendations for
the care and use of laboratory animals. The experiments were
approved by the SSI animal ethics board headed by DVM Kristin
E. Engelhart Illigen.
Animal Handling
Studies were performed with 6- to 8-week-old female F1
crossing of inbred male C57BL/6 and female Balb/c mice from
Harlan Scandinavia (CB6F1). This F1 mouse stain was used due to
broad recognition of vaccine antigens compared to the parent
strains. Mice were housed in appropriate animal facilities at
Statens Serum Institut and infected animals housed in cages
contained within laminar flow safety enclosures (Scantainer from
Scanbur, Denmark) in a separate biosafety level 3 facility at
Statens Serum Institut. All mice were fed radiation sterilized 2016
Global Rodent Maintenance diet (Harlan, Scandinavia) and water
ad libitum. All animals were allowed a one week rest prior to
initiation of the experiments.
Bacteria
M.tb Erdman was grown at 37uC on Middlebrook 7H11 (BD
Pharmingen) agar or in suspension in Sauton medium (BD
Pharmingen) enriched with 0.5% sodium pyruvate, 0.5% glucose,
and 0.2% Tween 80. BCG Danish strain 1331 was grown at 37uC
in Middlebrook 7H9 medium (BD Pharmingen). All bacteria were
grown to log phase and then stored at 280uC in growth medium
at ,5610
8 CFU/ml. Bacteria were thawed, placed in an
ultrasound-bath for five minutes, clumps dispersed by forcing
bacteria through a syringe, washed and diluted in PBS prior to
infection.
Antigens
Recombinant H4 (Ag85B-TB10.4) and Ag85B were produced
in E. coli and purified using column-purification as previously
described [21]. For restimulation of cell cultures with TB10.4,
peptide-mixtures with 18-mer peptides covering the antigen-
sequence with an overlap of 10 amino acids per peptide were used
at a final concentration of 2 mg/ml per single peptide in the
mixture [23]. For Ag85B and ESAT-6 restimulation, recombinant
Ag85B produced in E. coli was used. Cell cultures were all
stimulated with media only and ESAT-6 as a negative control
antigen before infections, as well as concanavalin A to assess cell
viability.
Immunizations and Experiment Protocols
Mice immunized with BCG received a single dose of
5610
6 CFU of BCG Danish 1331 per mouse injected s.c. in a
volume of 0.2 ml at the base of the tail at week 0 of the
experiment. Mice that received H4-IC31H were immunized two
times subcutaneously (s.c.) on the back at the base of the tail with
experimental vaccines containing 0.5 mg H4 formulated with the
IC31H adjuvant in a total volume of 200 ml 19 and 22 weeks after
BCG immunizations. The adjuvant IC31Hconsists of a mixture of
the peptide KLK (NH2-KLKL5KLK-COOH) and the oligodeox-
ynucleotide ODN1a (oligo-(dIdC)13) provided by Intercell. Doses
were 100 nmol peptide and 4 nmol oligonucleotide. Control mice
immunized with only H4-IC31H, without prior BCG-vaccination,
received H4-IC31H simultaneously with the BCG/H4-IC31H
boosted group (see figure 1A). Mice were challenged with M.tb
seven weeks after the last H4-IC31H booster (29 weeks post BCG).
Regarding the three experiments shown in figure S1, in
Experiment 1, mice were primed with BCG as described above
and boosted 34 and 36 weeks later with H4 emulsified in dimethyl
dioctadecyl ammonium bromide (DDA; 250 mg/dose; Eastman
Kodak) and monophosphoryl lipid A (MPL; 25 mg/dose; Avanti
Polar Lipids) in a volume of 0.2 ml, as described previously [21].
In this experiment, mice were challenged with M.tb five weeks
after the final booster vaccination. Bacterial levels were measured
six weeks after infection. The second experiment shown in figure
S1 (Exp. 2) is the same experiment as shown in figure 4, and the
third experiment (Exp. 3) is an exact replicate of experiment two
(where mice were challenged seven weeks after the final H4-IC31
booster and protection assessed six weeks later).
Experimental Infections and Enumeration of CFU to
Assess Protection
Mice challenged by the aerosol route were infected with
,100 CFU of M.tb Erdman/mouse with an inhalation exposure
system (Glas-Col) as previously described [21]. These mice were
killed 6 weeks after challenge. Numbers of bacteria in the spleen
and lung were determined by serial 3-fold dilutions of individual
whole-organ homogenates on 7H11 medium. Organs from the
BCG-vaccinated animals were grown on medium supplemented
with 2 mg of 2-thiophene-carboxylic acid hydrazide/ml to
selectively inhibit the growth of any residual BCG bacteria in
the test organs. Colonies were counted after 2–3 weeks of
incubation at 37uC. Protective efficacies were expressed as log10
bacterial counts in immunized mice compared with bacterial
counts in the controls.
Lymphocyte Cultures
PBMCs were purified on a density gradient using lympholyteH
for mammals (Cedarlane, Canada) and splenocyte and lung
lymphocyte cultures were obtained by passage of organs through a
100-mm nylon cell strainer (BD Pharmingen). After washing, cells
were cultured in roundbottom microtiter wells (96-well plates;
Nunc) containing 2610
5 cells in a volume of 200 ml of c-RPMI
(RPMI 1640 supplemented with 5610
25 M 2-ME, 1% (v/v)
premixed penicillin-streptomycin solution (Invitrogen Life Tech-
nologies), 1 mM glutamine, and 10% (v/v) FCS). Based on
previous dose-response investigations, the mycobacterial antigens
were all used at 2 mg/ml, whereas Concanavalin A was used at a
concentration of 1 mg/ml as a positive control for cell viability.
Supernatants from triplicate cultures were harvested from cultures
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ELISA. For intracellular cytokine analysis by flow cytometry,
122610
6 cells from blood, spleen or lung were cultured in c-
RPMI and stained as described below.
Cytokine ELISA
A sandwich ELISA was used to determine the concentration of
IFNc in culture supernatants, as described previously [24].
Flowcytometric Analysis
Intracellular cytokine staining of T cells was done as described
previously [24]. Briefly, cells were stimulated for 1 hour with
2 mg/ml antigen and subsequently incubated for 5 hours with
10 mg/ml brefeldin A (Sigma-Aldrich) at 37uC and then stained
for surface markers, permeabilized using the BD Biosciences
cytoperm/cytofix kit according to the manufacturer’s instructions
and subsequently stained for intracellular cytokine expression.
Samples were run on a FACS Canto six-colour flow cytometer
from BD Biosciences. All antibodies were purchased from BD
Biosciences except anti-IFNc, which was purchased from
eBioscience. In the results section, the percentage of total
responding CD4/CD8 T cells were determined by summing the
percentage of cells producing IFNc, TNFa or IL-2. The relative
proportions of cells producing different combinations were
calculated by Pestle and SPICE software and represent the
proportions of subpopulations relative to total responding CD4 or
CD8 T cells. Background responses from media controls were
subtracted.
Statistical Analysis
For comparisons of pulmonary responses measured after
infection by flow cytometry, individual subpopulations of T cells
were compared to non-vaccinated mice using 1-way ANOVA and
Bonferroni-correction for multiple comparisons (Fig. 3). For
multiple comparisons of CFUs, one-way ANOVA was used with
Newman-Keuls post-test for multiple comparisons and statistical
differences marked by asterisks in figures and explained in figure
legends. For statistical analysis of log10 protection individual
student’s t-test was made for each experiment. Correlations
between mean log10 CFUs and responses from ICS flow cytometry
were performed using Pearson’s product-moment correlation
coefficient (r) and correlation test. The coefficient of determination
(r
2) shows the amount of variation shared by the two variables.
Graphpad prism 5.0 software was used for analysis.
Supporting Information
Figure S1 Boosting with H4 improves suboptimal BCG-
derived protection. In three separate experiments the level of
protection observed from BCG/H4 booster groups was compa-
rable. However, H4-boosting only significantly improved BCG-
derived protection when protection from BCG itself was below 1.1
log10 CFU in the lungs. In experiment number one BCG was
boosted with H4-DDA/MPL. In experiment two and three
boosting was performed with H4-IC31H (see Materials and
Methods for details). Bars represent individual log10 CFU values
deducted with the mean value of the non-vaccinated control group
from the same experiment. *, p,0.05 analysed by student’s t-test
comparing log10 reduction in CFU in the lungs for each
experiment separately.
(TIF)
Figure S2 CD8 T cell response correlate with CFU levels
six weeks after infection. A, the pulmonary responses
obtained using ICS and flow cytometry six weeks after infection
shown in figure 3 after stimulation with Ag85B, TB10.4 or ESAT-
6 were correlated to the corresponding mean log10 CFU value
shown in figure 4. Points represent mean percentage and SEM
(vertical) of CD8 T cells producing IFNc in response to stimulation
with indicated antigens from 3 pools of two lungs plotted on the y-
axis and mean and SEM (horizontal) log10 CFU values of mice
lungs (N=29 for non-vaccinated controls and n=9210 for the
vaccination groups) on the x-axis. Each point represents one group
in the order BCG/H4-IC31, BCG, H4-IC31, and non vaccinated
from left. *, p,0.05, **, p,0.01, using Pearson’s product-moment
correlation coefficient (r) and correlation test. B, pulmonary CD8
T cell responses six weeks after infection. Lung lymphocytes from
three pools consisting of two half lungs per pool were used from
each group for intracellular cytokine analysis by flow cytometry.
Cells were stimulated with the antigens specified in the graph. Bars
represent the proportions of lung CD8 T cell subsets producing
different cytokines in response to stimulation as indicated on the
X-axis. Background levels obtained in media-stimulated samples
has been deducted. *, p,0.05, **, p,0.01, ***, p,0.001,
proportion of cytokine producing CD8 T cells subsets compared
to non-vaccinated controls using one-way ANOVA and Tukey’s
post-test for multiple comparisons.
(TIF)
Table S1 Percentages of lung T cells producing cyto-
kines in the different groups as well as the correspond-
ing log10 CFU values with SD and SEM. Log10 CFU values
with SD and SEM are shown for each group, as well as the
percentage of lung CD4 T cells producing IFN-c, TNFa and IL-2
simultaneously after stimulation with the indicated antigens
analysed by intracellular cytokine staining and flow cytometry. *
Three pools consisting of two half lungs per pool were used from
each group for stimulation.
(XLSX)
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